Hong Kong Wireless Telecom Stock News

As geopolitical tensions and energy price volatility continue to influence global markets, investors in Asia are navigating a complex landscape marked by both challenges and opportunities. In such an environment, growth companies with significant insider ownership can offer a unique investment angle, as they often reflect strong confidence from those closest to the business.

As geopolitical tensions and energy price volatility continue to influence global markets, Asia's stock indices have experienced mixed outcomes, with investor sentiment swaying in response to these developments. Amidst this uncertainty, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking resilience and growth. In the current market climate, a good stock might be characterized by strong fundamentals and the...

CALB Group (SEHK:3931) closed out FY 2025 with Q4 revenue of C¥15.9b and net income of C¥791.0m, while trailing twelve month revenue reached C¥44.4b and net income came in at C¥1.48b. Over the past few quarters the company has seen revenue move from C¥6.6b in Q3 2024 to C¥6.9b in Q1 2025, C¥9.5b in Q2, C¥12.1b in Q3 and C¥15.9b in Q4. Quarterly net income shifted from a loss of C¥68.7m in Q3 2024 to profits of C¥230.2m, C¥235.8m, C¥218.6m and C¥791.0m respectively, alongside trailing EPS of...

As global markets navigate the complexities of geopolitical tensions and energy price volatility, Asian markets are also feeling the ripple effects, with investor sentiment being shaped by these macroeconomic shifts. In this environment, identifying emerging stocks that show resilience and adaptability can be key to uncovering potential opportunities in Asia's dynamic economic landscape.

Amidst the backdrop of geopolitical tensions and fluctuating energy prices, Asian markets are navigating a complex landscape that has investors on edge. While large-cap stocks often dominate headlines, penny stocks—despite their old-fashioned name—remain an intriguing option for those seeking to explore smaller or newer companies with potential upside. By focusing on firms with strong financials and growth prospects, investors can uncover hidden value in these lesser-known equities.

Newborn Town (SEHK:9911) has drawn renewed attention to its stock after reporting its 2025 annual results and unveiling a new share repurchase program of up to HK$300 million, funded from internal resources. See our latest analysis for Newborn Town. Newborn Town’s share price has softened in recent months, with a 30 day share price return of 14.24% and a year to date share price return decline of 31.51%. At the same time, the 3 year total shareholder return of about 7x and 1 year total...

Zylox-Tonbridge Medical Technology (SEHK:2190) has drawn attention after reporting full year 2025 earnings, with sales of CNY 1,057.49 million and net income of CNY 244.37 million, alongside a proposed ordinary final dividend. See our latest analysis for Zylox-Tonbridge Medical Technology. The latest earnings and dividend proposal sit alongside share price momentum that has been building over the past month, with a 10.09% 1 month share price return and a 49.00% 1 year total shareholder...

Sinotruk (Hong Kong) (SEHK:3808) has put up another set of solid numbers for FY 2025, with first half revenue at about C¥50.9b and basic EPS of C¥1.25, backed by trailing twelve month revenue of roughly C¥109.5b and EPS of C¥2.57. Over the past three reported halves, revenue has moved from C¥48.8b in 1H 2024 to C¥46.2b in 2H 2024 and then to C¥50.9b in 1H 2025. Basic EPS tracked at C¥1.20, C¥0.94 and C¥1.25 respectively, supported by trailing twelve month EPS that stepped up from C¥2.14 to...

Recent share performance and business snapshot InnoCare Pharma (SEHK:9969) has drawn investor attention after a 5.7% one day gain, adding to a one month return of 12.8% and a past 3 months return recorded as 0%. The Hong Kong listed biopharmaceutical group focuses on cancer and autoimmune disease treatments in China, with revenue of CN¥2,374.906 million and net income of CN¥642.467 million reported in its latest figures. See our latest analysis for InnoCare Pharma. At the current share price...

Earnings and Contract Win Set the Scene for Wasion Holdings Wasion Holdings (SEHK:3393) has drawn fresh attention after reporting full year 2025 earnings, alongside securing an exclusive recloser supply contract with Brazilian power group Companhia Energética de Minas Gerais S.A. See our latest analysis for Wasion Holdings. The recent earnings release and Brazilian contract news arrive after a strong run in the shares, with a 90 day share price return of 75.81% and a 1 year total shareholder...

Wondering whether CNOOC’s current share price still offers value after a strong run, or if you may be turning up late to the story. CNOOC shares last closed at HK$29.06, with returns of 17.8% over 30 days, 32.9% year to date, and 69.2% over 1 year, while the 7 day return shows a 4.3% pullback that may have changed how investors view the near term risk and reward. Recent news flow around CNOOC has focused on its role in global energy markets and investor attention on large oil and gas...

The latest earnings release for MGM China Holdings (SEHK:2282), combined with a proposed final ordinary dividend of HK$0.353 per share, has drawn fresh attention to how the stock reflects these updated fundamentals. See our latest analysis for MGM China Holdings. Despite a 2.27% 1 day share price return to HK$11.24, the 30 day and 90 day share price returns of 11.01% and 27.86% declines suggest momentum has recently faded, even as the 1 year and 3 year total shareholder returns of 8.45% and...

Why Kingdee’s latest results are drawing fresh attention Kingdee International Software Group (SEHK:268) is back in focus after its full year 2025 results showed CNY 7,006.04 million in sales and net income of CNY 92.91 million, compared with a loss a year earlier. See our latest analysis for Kingdee International Software Group. At a share price of HK$8.83, Kingdee’s 1 day share price return of 0.91% sits against weaker recent momentum. This includes a 30 day share price return of 10.63% and...

Earnings trigger and why it matters now Bank of Chongqing (SEHK:1963) has drawn fresh attention after reporting its full year 2025 results, with net interest income at CN¥12,459.41 million and net income at CN¥5,654.22 million, both higher than the previous year. See our latest analysis for Bank of Chongqing. At a share price of HK$7.97, Bank of Chongqing has seen a 3.64% 1 month share price return, while its 1 year total shareholder return of 26.65% and 3 year total shareholder return of...

361 Degrees International (SEHK:1361) has drawn renewed attention to its stock after reporting full year 2025 results and recommending a higher final dividend, aligning earnings and shareholder payouts more closely. See our latest analysis for 361 Degrees International. At a share price of HK$6.0, the stock has added momentum recently, with a 7 day share price return of 11.94% and a 1 year total shareholder return of 41.19%. This suggests growing optimism after the earnings and dividend...

Sunshine Insurance Group Company Limited reported past full-year 2025 results, with net income of CNY 6,307 million and basic earnings per share of CNY 0.55, and proposed a final cash dividend of CNY 0.19 per ordinary share payable on 28 July 2026. The combination of higher earnings per share and a cash dividend proposal highlights how Sunshine Insurance Group is balancing profitability with direct capital returns to shareholders. Against this backdrop, we will examine how the company’s...

China Construction Bank (SEHK:939) has laid out its FY 2025 scorecard with fourth quarter revenue of CNY 169.0b and basic EPS of CNY 0.30, alongside trailing twelve month revenue of CNY 607.6b and EPS of CNY 1.30. Over recent periods, revenue has ranged from CNY 165.1b in Q4 2024 to CNY 169.0b in Q4 2025, while quarterly EPS has held around CNY 0.30 to CNY 0.35. This presents a picture of steady top line scale supported by high margins, framing the latest results as a balance of income...

Why Keymed Biosciences just drew fresh attention Keymed Biosciences (SEHK:2162) has come into focus after releasing its 2025 annual results, with higher reported sales, a wider net loss in absolute terms, and a slightly smaller loss per share from continuing operations. See our latest analysis for Keymed Biosciences. The latest earnings release and wider shift toward commercialization appear to be feeding into stronger momentum, with a 1-day share price return of 5.03% and a 1-year total...

Haina Intelligent Equipment International Holdings (SEHK:1645) has reported FY 2025 first half revenue of C¥224.2 million and basic EPS of C¥0.0156, while the trailing twelve months show revenue of C¥411.4 million and a net loss of C¥17.7 million with basic EPS of C¥0.0314. Over recent periods, the company has seen revenue move from C¥182.4 million and basic EPS of C¥0.0206 in the first half of FY 2024 to C¥187.3 million with basic EPS of C¥0.0470 in the second half, before reaching the...

China Cultural Tourism and Agriculture Group (SEHK:542) has reported FY 2025 first half revenue of HK$35.6 million with a basic EPS loss of HK$0.034. On a trailing twelve month basis, revenue stands at HK$238.3 million against a net loss of HK$167.8 million and basic EPS of HK$0.109. Over recent periods the company has seen revenue move from HK$13.5 million in 1H 2024 to HK$202.7 million in 2H 2024 and HK$35.6 million in 1H 2025. Net losses were HK$88.2 million, HK$115.3 million and HK$52.5...

Guangzhou Rural Commercial Bank (SEHK:1551) has reported its FY 2025 first half results with total revenue of C¥4,229.2 million and basic EPS of C¥0.07, alongside net income excluding extra items of C¥1,040.7 million. The trailing twelve month figures show revenue of C¥7,862.0 million and EPS of C¥0.11. Over the last reported periods, revenue has moved from C¥4,279.7 million and EPS of C¥0.05 in the second half of 2023 to C¥4,430.0 million and EPS of C¥0.06 in the first half of 2024, before...

Wuhan YZY Biopharma (SEHK:2496) has just posted its FY 2025 first half numbers, with revenue of C¥44.4 million and a basic EPS loss of C¥0.30 per share, alongside trailing 12 month revenue of C¥149.3 million and a basic EPS loss of C¥0.40. Over recent periods the company has seen revenue move from C¥2.8 million in 1H 2024 to C¥105.0 million in 2H 2024 and C¥44.4 million in 1H 2025. Over the same intervals, EPS shifted from a loss of C¥0.40 to a loss of C¥0.10 and then a loss of C¥0.30 per...

China XLX Fertiliser Ltd. has reported its full-year 2025 results, with sales rising to CNY 25,352.47 million while net income fell to CNY 932.02 million, reducing both basic and diluted earnings per share versus 2024. The combination of higher revenue but lower earnings suggests that cost pressures or margin changes played a significant role in shaping the 2025 outcome. We’ll now examine how the rise in sales alongside weaker earnings reshapes China XLX Fertiliser’s investment narrative for...

Grand Pharmaceutical Group (SEHK:512) has just posted its full year 2025 results, reporting higher sales, sharply lower net income, a reduced annual dividend, and fresh NMPA approval for ophthalmic drug GPN01768. See our latest analysis for Grand Pharmaceutical Group. The share price is HK$6.78 after a 3.04% 1 day share price return. The 30 day share price return of 12.52% and year to date share price return of 13.08% point to fading short term momentum despite a 3 year total shareholder...